There are several companies working in the field of cancer research. Seattle Genetics is occupying a unique place here. The CEO of this company is Clay Siegall. This is a company that is focused on several innovations it makes its advancements in the field of cancer therapy. Thus the stock prices of this company have tripled over the past five years. It also indicates the importance of this company in the field of cancer research.
Dr. Clay Siegall has a passion for improving the lives of those who are suffering from cancer. This has been with him ever since he started his career in biomedical studies. He is serving as the President, CEO, and even the Chairman of the Board at Seattle Genetics. Since 2002, Clay Siegall has been the chief executive officer of Seattle Genetics which he co-founded. He has over 20 years of experience. This is why he has been able to lead it to great advancements in the field of cancer research. He has managed to achieve several ground-breaking therapies which can be used for the treatment of cancer patients.
He holds a Ph.D. in Genetics from the George Washington University. Clay Siegall has a long list of professional accomplishments to his name. His career had started as a Senior Research Investigator with the Bristol-Myers Squibb Pharmaceutical Research Institute. After his promotion, he became the Principal Scientist over here. He moved on to become a Staff Fellow as well as Biotechnology Fellow at the National Cancer Institute. Next, Clay Siegall moved on to co-found Seattle Genetics.
Clay Siegall is known for his commitment towards conducting important research. He wants to implement all the latest developments in research methodologies. This is because of his consistent desire to help those who are suffering from cancer. His motivation is to alleviate their suffering. This passion has managed to help Clay Siegall in taking the company to new heights of success with regard to advancements in its research. Under the leadership of Clay Siegall, Seattle Genetics developed its first antibody-drug conjugates. These include ADCETRIS®. It was in 2011 that it could secure FDA approval.